WO2001000175A1 - Formes d'administration pharmaceutiques mecaniquement stables, contenant des agents tensioactifs liquides ou semi-solides - Google Patents

Formes d'administration pharmaceutiques mecaniquement stables, contenant des agents tensioactifs liquides ou semi-solides Download PDF

Info

Publication number
WO2001000175A1
WO2001000175A1 PCT/EP2000/005494 EP0005494W WO0100175A1 WO 2001000175 A1 WO2001000175 A1 WO 2001000175A1 EP 0005494 W EP0005494 W EP 0005494W WO 0100175 A1 WO0100175 A1 WO 0100175A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparations according
active substance
active
preparations
active substances
Prior art date
Application number
PCT/EP2000/005494
Other languages
German (de)
English (en)
Inventor
Gunther Berndl
Jörg Rosenberg
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of WO2001000175A1 publication Critical patent/WO2001000175A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des préparations se présentant sous la forme de solutions solides de principes actifs pharmaceutiques contenues dans une matrice de substance auxiliaire qui contient, comme composant polymère, un homopolymère ou un copolymère de la N-vinylpyrrolidone, ainsi qu'un agent tensioactif qui est liquide à 20 °C ou dont le point de goutte est compris entre 20 °C et 50 °C.
PCT/EP2000/005494 1999-06-25 2000-06-15 Formes d'administration pharmaceutiques mecaniquement stables, contenant des agents tensioactifs liquides ou semi-solides WO2001000175A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999129361 DE19929361A1 (de) 1999-06-25 1999-06-25 Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361.9 1999-06-25

Publications (1)

Publication Number Publication Date
WO2001000175A1 true WO2001000175A1 (fr) 2001-01-04

Family

ID=7912675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005494 WO2001000175A1 (fr) 1999-06-25 2000-06-15 Formes d'administration pharmaceutiques mecaniquement stables, contenant des agents tensioactifs liquides ou semi-solides

Country Status (2)

Country Link
DE (1) DE19929361A1 (fr)
WO (1) WO2001000175A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143074A2 (fr) 2009-06-08 2010-12-16 Abbott Gmbh & Co. Kg Forme posologique pharmaceutique pour l'administration orale d'un inhibiteur de la famille de bcl-2
WO2012121758A1 (fr) 2010-10-29 2012-09-13 Abbvie Inc. Dispersions solides extrudées en fusion contenant un agent induisant l'apoptose
US8268349B2 (en) 2003-08-28 2012-09-18 Abbott Laboratories Solid pharmaceutical dosage form
US8470347B2 (en) 2000-05-30 2013-06-25 AbbVie Deutschland GmbH and Co KG Self-emulsifying active substance formulation and use of this formulation
WO2014048783A1 (fr) 2012-09-27 2014-04-03 Basf Se Formulation particulaire homogène sans poussière stable en stockage comprenant au moins un dérivé de vitamine e hydrosoluble et au moins un polymère hydrophile
WO2014048782A1 (fr) 2012-09-27 2014-04-03 Basf Se Formulation particulaire homogène sans poussière stable en stockage comprenant au moins un dérivé de vitamine e hydrosoluble et au moins un polymère hydrophile
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8927009B2 (en) 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
US9078921B2 (en) 2006-07-19 2015-07-14 Abbvie Deutschland Gmbh & Co Kg Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US9096556B2 (en) 2011-05-27 2015-08-04 Hetero Research Foundation Amorphous ritonavir co-precipitated
US9107830B2 (en) 1999-11-12 2015-08-18 Abbvie, Inc. Inhibitors of crystallization in a solid dispersion
US9345702B2 (en) 2010-11-23 2016-05-24 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
US10081628B2 (en) 2013-03-14 2018-09-25 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US10213433B2 (en) 2010-10-29 2019-02-26 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
CN109789140A (zh) * 2016-09-21 2019-05-21 伊兹瓦里诺帕玛有限责任公司 用于治疗hiv感染的药物组合物
WO2021173523A1 (fr) 2020-02-24 2021-09-02 Newave Pharmaceutical Inc. Dispersions solides extrudées à chaud contenant un inhibiteur de bcl2

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000273A1 (fr) * 2003-06-27 2005-01-06 Bioprogress S.P.A. Produit composite obtenu par broyage d'un principe actif avec un copolymere n-vinyle-2-pyrrolidone/vinyle-acetate
EP1920767A1 (fr) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Forme posologique d'Imatinib préparée à l'état fondu.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011749A1 (fr) * 1991-12-18 1993-06-24 Warner-Lambert Company Procede de preparation d'une dispersion solide
WO1996022103A1 (fr) * 1995-01-21 1996-07-25 Cheil Foods & Chemicals, Inc. Formulations solides pour l'administration de cyclosporine a par voie orale
US5776495A (en) * 1994-07-26 1998-07-07 Laboratoires Effik Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
DE19753298A1 (de) * 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
WO2000057854A2 (fr) * 1999-03-25 2000-10-05 Basf Aktiengesellschaft Formes d'administration pharmaceutiques mecaniquement stables, qui contiennent des substances tensioactives liquides ou semi-solides
WO2000057855A1 (fr) * 1999-03-25 2000-10-05 Basf Aktiengesellschaft Auxiliaires de solubilisation pulverulents pour formes d'administration pharmaceutiques solides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011749A1 (fr) * 1991-12-18 1993-06-24 Warner-Lambert Company Procede de preparation d'une dispersion solide
US5776495A (en) * 1994-07-26 1998-07-07 Laboratoires Effik Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
WO1996022103A1 (fr) * 1995-01-21 1996-07-25 Cheil Foods & Chemicals, Inc. Formulations solides pour l'administration de cyclosporine a par voie orale
DE19753298A1 (de) * 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
WO2000057854A2 (fr) * 1999-03-25 2000-10-05 Basf Aktiengesellschaft Formes d'administration pharmaceutiques mecaniquement stables, qui contiennent des substances tensioactives liquides ou semi-solides
WO2000057855A1 (fr) * 1999-03-25 2000-10-05 Basf Aktiengesellschaft Auxiliaires de solubilisation pulverulents pour formes d'administration pharmaceutiques solides

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107830B2 (en) 1999-11-12 2015-08-18 Abbvie, Inc. Inhibitors of crystallization in a solid dispersion
US8470347B2 (en) 2000-05-30 2013-06-25 AbbVie Deutschland GmbH and Co KG Self-emulsifying active substance formulation and use of this formulation
US8399015B2 (en) 2003-08-28 2013-03-19 Abbvie Inc. Solid pharmaceutical dosage form
US8333990B2 (en) 2003-08-28 2012-12-18 Abbott Laboratories Solid pharmaceutical dosage form
US8268349B2 (en) 2003-08-28 2012-09-18 Abbott Laboratories Solid pharmaceutical dosage form
US8309613B2 (en) 2003-08-28 2012-11-13 Abbvie Inc. Solid pharmaceutical dosage form
US8691878B2 (en) 2003-08-28 2014-04-08 Abbvie Inc. Solid pharmaceutical dosage form
US9616130B2 (en) 2006-07-19 2017-04-11 Abbvie Deutschland Gmbh & Co Kg Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US9078921B2 (en) 2006-07-19 2015-07-14 Abbvie Deutschland Gmbh & Co Kg Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
WO2010143074A2 (fr) 2009-06-08 2010-12-16 Abbott Gmbh & Co. Kg Forme posologique pharmaceutique pour l'administration orale d'un inhibiteur de la famille de bcl-2
US9642796B2 (en) 2009-06-08 2017-05-09 Abbvie Inc. Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor
EP2982366A1 (fr) 2009-06-08 2016-02-10 Abbott GmbH & Co. KG Forme posologique pharmaceutique pour l'administration orale d'un inhibiteur de la famille bcl-2
EP3272334A1 (fr) 2009-06-08 2018-01-24 Abbott GmbH & Co. KG Forme posologique pharmaceutique pour l'administration orale d'un inhibiteur de la famille bcl-2
US8927009B2 (en) 2009-12-22 2015-01-06 Abbvie Inc. ABT-263 capsule
EP4218731A2 (fr) 2010-10-29 2023-08-02 AbbVie Ireland Unlimited Company Dispersions solides extrudées à l'état fondu contenant un agent induisant l'apoptose
WO2012121758A1 (fr) 2010-10-29 2012-09-13 Abbvie Inc. Dispersions solides extrudées en fusion contenant un agent induisant l'apoptose
US10213433B2 (en) 2010-10-29 2019-02-26 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
EP3219308A1 (fr) 2010-10-29 2017-09-20 AbbVie Ireland Unlimited Company Dispersions solides extrudées par fusion contenant un agent induisant l'apoptose
US11369599B2 (en) 2010-10-29 2022-06-28 Abbvie Inc. Melt-extruded solid dispersions containing an apoptosis-inducing agent
US9840502B2 (en) 2010-11-23 2017-12-12 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US10730873B2 (en) 2010-11-23 2020-08-04 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US9345702B2 (en) 2010-11-23 2016-05-24 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US9238649B2 (en) 2010-11-23 2016-01-19 Abbvie Inc. Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
US9872861B2 (en) 2010-11-23 2018-01-23 Abbvie Inc. Methods of treatment using selective Bcl-2 inhibitors
US9096556B2 (en) 2011-05-27 2015-08-04 Hetero Research Foundation Amorphous ritonavir co-precipitated
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
WO2014048782A1 (fr) 2012-09-27 2014-04-03 Basf Se Formulation particulaire homogène sans poussière stable en stockage comprenant au moins un dérivé de vitamine e hydrosoluble et au moins un polymère hydrophile
WO2014048783A1 (fr) 2012-09-27 2014-04-03 Basf Se Formulation particulaire homogène sans poussière stable en stockage comprenant au moins un dérivé de vitamine e hydrosoluble et au moins un polymère hydrophile
US10081628B2 (en) 2013-03-14 2018-09-25 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN109789140A (zh) * 2016-09-21 2019-05-21 伊兹瓦里诺帕玛有限责任公司 用于治疗hiv感染的药物组合物
WO2021173523A1 (fr) 2020-02-24 2021-09-02 Newave Pharmaceutical Inc. Dispersions solides extrudées à chaud contenant un inhibiteur de bcl2

Also Published As

Publication number Publication date
DE19929361A1 (de) 2001-01-04

Similar Documents

Publication Publication Date Title
EP1162953B1 (fr) Formes d'administration pharmaceutiques mecaniquement stables, qui contiennent des substances tensioactives liquides ou semi-solides
EP1318799B1 (fr) Formes galeniques stables contenant des ubiquinones
WO2001000175A1 (fr) Formes d'administration pharmaceutiques mecaniquement stables, contenant des agents tensioactifs liquides ou semi-solides
EP1166776B1 (fr) Procédé de préparation de formes orales solides à libération retardée
DE69434640T2 (de) Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe
DE4031881C2 (de) Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
EP1001757B1 (fr) Antalgique d'action rapide
EP0596203B1 (fr) Préparations sous forme de particules solides contenant des principes actifs et des polymères hydrosolubles
WO1998052684A1 (fr) Procede de preparation de compositions a fines particules de substances biologiquement actives
DE69730241T2 (de) Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
EP1478344B1 (fr) Extrusion de fusion de sels d'agents actifs
DE3424553A1 (de) Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
EP1280534B1 (fr) Preparations pharmaceutiques stables au stockage contenant du torasemide
EP1142571B1 (fr) Procédé pour la production de formes galéniques solides à base de créatine et formes galéniques ainsi obtenues
DE19913606A1 (de) Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
WO2001007015A2 (fr) Extrudats a liberation rapide, leur procede de production et preparations pouvant etre obtenues partir desdits extrudats
EP1059914A2 (fr) Procede de production de corps moules spheriques solides contenant des principes actifs pharmaceutiques dans une matrice constituee d'un liant
DE19901040A1 (de) Arzneiformen mit gesteuerter Freisetzung, enthaltend gut wasserlösliche Wirkstoffe
WO2001001956A2 (fr) Preparations solides contenant de la paroxetine
WO2001030372A2 (fr) Preparations de principes actifs pharmaceutiques
DE60312635T3 (de) Zusammensetzung in Form eines festen Dispersion enthaltend Itraconazol und ein hydrophilisches Polymer mit einer verbesserten Bioverfügbarkeit
DE102008057285A1 (de) 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP